IP Verse

Dosing Regimen For Anti-Bcma Agents

Patent No. EP3819007 (titled "Dosing Regimen For Anti-Bcma Agents") was filed by Amgen on Nov 11, 2019. The application was issued on Jul 10, 2024.

Patent Summary

A method and construct for treating BCMA-positive neoplasms through targeted antibody therapy that enhances half-life and improves efficacy. The construct comprises a BCMA-specific antibody with a CD3-binding domain and a Fc-terminal extension, administered in a regimen of at least three administrations per cycle. The antibody binds to BCMA on plasma cells, while the Fc-terminal extension extends its half-life, enabling sustained therapeutic effects. This approach combines the specificity of BCMA targeting with the enhanced stability of a modified antibody construct.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ABBVIEApr 9, 2025KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF
REGENERON PHARMACEUTICALSAug 2, 2024CARPMAELS & RANSFORD
STRAWMANJul 11, 2024RCF PROTECTING INNOVATION

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3819007

AMGEN
Application Number
EP19208417A
Filing Date
Nov 11, 2019
Status
Granted And Under Opposition
Jun 7, 2024
Publication Date
Jul 10, 2024
External Links
Slate, Register , Google Patents